Renerve (ASX:RNV) FCF Margin %: -1,791.46% (As of Dec. 2025)


What is Renerve FCF Margin %?

Renerve ASX:RNV +1.27% FCF Margin % is -1,791.46% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 948 Biotechnology companies, Renerve ranks worse than 81.86% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Renerve's Free Cash Flow for the six months ended in Dec. 2025 was A$-2.94 Mil. Renerve's Revenue for the six months ended in Dec. 2025 was A$0.16 Mil. Therefore, Renerve's FCF Margin % for the quarter that ended in Dec. 2025 was -1,791.46%.

As of today, Renerve's current FCF Yield % is -33.55%.

The historical rank and industry rank for Renerve's FCF Margin % or its related term are showing as below:

ASX:RNV' s FCF Margin % Range Over the Past 10 Years
Min: -1371.17   Med: -1153.06   Max: -341.7
Current: -1371.17

During the past 4 years, the highest FCF Margin % of Renerve was -341.70%. The lowest was -1371.17%. And the median was -1153.06%.

ASX:RNV's FCF Margin % is ranked worse than
81.86% of 948 companies
in the Biotechnology industry
Industry Median: -81.28 vs ASX:RNV: -1371.17

Renerve FCF Margin % Related Terms

Renerve FCF Margin % Historical Data

* Premium members only.

The historical data trend for Renerve's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renerve FCF Margin % Chart

Renerve Annual Data
Trend Jun22 Jun23 Jun24 Jun25
FCF Margin %
-341.70 -1,185.16 -1,298.31 -1,120.96

Renerve Semi-Annual Data
Jun22 Jun23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial 0.00 0.00 -1,394.12 -963.31 -1,791.46

ASX:RNV vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Renerve's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renerve FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renerve's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Renerve's FCF Margin % falls into.


Renerve FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Renerve's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.049/0.272
=-1,120.96 %

Renerve's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.938/0.164
=-1,791.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -1,791.46% mean?
Renerve (ASX:RNV) has a FCF Margin % of -1,791.46% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Renerve and its competitors. According to the industry distribution chart, Renerve ranks #776 out of 948 companies in the Biotechnology industry, placing it in the top 81.9%.
Is Renerve's FCF Margin % too high?
Renerve's current FCF Margin % is -1,791.46%. Based on the distribution chart, Renerve ranks #776 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Renerve's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Renerve ranks #776 out of 948 companies for FCF Margin %. This places Renerve in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Renerve and its competitors. Renerve's current FCF Margin % is -1,791.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renerve stock overvalued right now?
Renerve (ASX:RNV) has a current FCF Margin % of -1,791.46%. The current FCF Margin % is -1,791.46%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Renerve (ASX:RNV), the current FCF Margin % is -1,791.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renerve Business Description

Address 157 Heidelberg Road, Northcote, VIC, AUS, 3070
Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA.